SSA
SCPS

Schonfeld Strategic Advisors’s Scopus BioPharma Inc. Common Stock SCPS Stock Holding History

Schonfeld Strategic Advisors’s Portfolio SCPS Stock Details SCPS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-15,000
Closed -$223K – 2238
2020
Q4 		$223K Buy
+15,000
New +$266K ﹤0.01% 1307

Other funds holding SCPS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Schonfeld Strategic Advisors's SCPS Position: Q1 2021 in Review

Schonfeld Strategic Advisors sold out of Scopus BioPharma Inc. Common Stock (SCPS) in Q1 2021, closing a stake of 15,000 shares — an estimated $223K sold.

Schonfeld Strategic Advisors first reported a position in SCPS in Q4 2020 and held it in 1 quarter. The position peaked at $223K in Q4 2020. 28 funds tracked by Wall St. Rank hold SCPS as of Q1 2021.

  • Schonfeld Strategic Advisors reported no remaining Scopus BioPharma Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 15,000 Scopus BioPharma Inc. Common Stock shares in Q1 2021, an estimated $223K.
  • Schonfeld Strategic Advisors first reported a position in Scopus BioPharma Inc. Common Stock in Q4 2020 and held it in 1 quarter.
  • Schonfeld Strategic Advisors's Scopus BioPharma Inc. Common Stock position peaked at $223K in Q4 2020.
  • 28 funds tracked by Wall St. Rank held Scopus BioPharma Inc. Common Stock as of Q1 2021.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2021, filed 17 May 2021.